A new 48-week trial, that was presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting, shows that adults with peanut allergies who received oral immunotherapy in the form of a specially developed toothpaste with tiny amounts of peanut allergens didn’t experience neither moderate nor severe allergic reactions to an escalating dose of the allergen.
In the current study, the research team assessed immune responses to the allergens in the toothpaste by checking blood biomarkers combined with conducting oral “food challenges” to measure allergic responses under the observation of medical experts.
Lead author, Dr. William Berger, a pediatric allergist at the Children’s Hospital of Orange County in California, says: “We noted that 100 percent of those being treated with the toothpaste consistently tolerated the pre-specified protocol highest dose. No moderate nor severe systemic reactions occurred in active participants. Non-systemic adverse reactions were mostly local (oral itching), mild, and transient.”